Find your next paid study

~$10 – $6,250

Mayo ClinicNCT07285044

Advanced Fallopian Tube CarcinomaAdvanced Fallopian Tube High Grade Serous AdenocarcinomaAdvanced Ovarian Carcinoma+15 more

MC1963 Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for Patients With Advanced Stage Ovarian Cancer: A Phase II Double-Blind Randomized Clinical Trial (FAROUT)

This phase II trial compares the effect of folate receptor alpha dendritic cells (FRαDCs) to placebo in treating patients with stage III or IV ovarian, fallopi…

~$10 – $6,250

Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+12 more

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients …

National Cancer Institute (NCI)

~$10 – $5,625

Gynecologic CancersPlatinum-Sensitive Ovarian CancerFallopian Tube Cancer+1 more

A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability …

A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, F…

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05128825

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more

A Randomized Phase II Trial of Sacituzumab Govitecan-HZIY (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizuma…

~$10 – $5,625

Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy …

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatm…

Ovarian CancerFallopian Tube Cancer

M.D. Anderson Cancer CenterNCT05287451

~$10 – $6,250

Phase 1

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and a…

Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer+6 more

Avenzo Therapeutics, Inc.NCT05867251

Phase 1

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to …

Recurrent Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Primary Peritoneal Cancer+3 more

Regeneron PharmaceuticalsNCT03564340

Phase 1

A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies

This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both c…

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more

Regeneron PharmaceuticalsNCT04590326

Phase 3

A Phase 3, Randomized, Open-label Study of Raludotatug Deruxtecan (MK-5909, R-DXd) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly-Diagnosed Advanced Non-HRD-Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (ENGOT-ov102/MITO/GOG-3141/ REJOICE-Ovarian 04)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible.…

Ovarian CancerOvarian NeoplasmsPeritoneal Cancer+1 more